Diplomat Pharmacy to dispense latest AstraZeneca cancer remedy

FLINT, Mich. - Diplomat Pharmacy announced Monday that it will offer Tagrisso (osimertinib), recently approved by the U.S. Food and Drug Administration as an oral therapy for a specific type of metastatic non-small cell lung cancer.

 

Tagrisso is an EGFR-tyrosine kinase inhibitor, a targeted cancer therapy, designed to inhibit both the activating, sensitizing mutations, and T790M, the genetic mutation responsible for EGFR-TKI treatment resistance in up to approximately two-thirds of cases of EGFRm advanced NSCLC. 

 

"Diplomat is proud to support patient adherence and compliance with therapy through enhanced clinical outreach programs, with customized messaging, developed in collaboration with AstraZeneca, to patients through various stages of treatment," said Gary Kadlec, Diplomat president.